🔬 New Insights on MASLD from JAMA 🍃
I recently reviewed an excellent JAMA article on Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)—now recognized as the most common chronic liver disease worldwide. The review highlights how metabolic dysfunction, inflammation, and fibrosis converge to drive long-term risks, including cardiovascular disease, hepatocellular carcinoma, and extrahepatic cancers.
Key advances include better noninvasive fibrosis assessment (FIB-4, elastography), strong evidence for lifestyle-driven weight loss, and new therapeutic momentum with resmetirom and semaglutide for MASH with fibrosis.
As MASLD incidence accelerates globally, this synthesis underscores the urgency of early detection, metabolic risk control, and multidisciplinary care. 🌍💡
